IS5276A - Tartrat salt af setnu dípeptíði sem vaxtarhormónsseytir - Google Patents

Tartrat salt af setnu dípeptíði sem vaxtarhormónsseytir

Info

Publication number
IS5276A
IS5276A IS5276A IS5276A IS5276A IS 5276 A IS5276 A IS 5276A IS 5276 A IS5276 A IS 5276A IS 5276 A IS5276 A IS 5276A IS 5276 A IS5276 A IS 5276A
Authority
IS
Iceland
Prior art keywords
growth hormone
tartrate salt
hormone secretion
substituted dipeptide
dipeptide
Prior art date
Application number
IS5276A
Other languages
English (en)
Inventor
Albert Carpino Philip
Andrew Dasilva-Jardine Paul
Allen Lefker Bruce
Anthony Murry Jerry
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5276A publication Critical patent/IS5276A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
IS5276A 1997-06-25 1999-11-26 Tartrat salt af setnu dípeptíði sem vaxtarhormónsseytir IS5276A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5072397P 1997-06-25 1997-06-25
PCT/IB1998/000874 WO1998058948A1 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue

Publications (1)

Publication Number Publication Date
IS5276A true IS5276A (is) 1999-11-26

Family

ID=21966996

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5276A IS5276A (is) 1997-06-25 1999-11-26 Tartrat salt af setnu dípeptíði sem vaxtarhormónsseytir

Country Status (40)

Country Link
US (2) US6248717B1 (is)
EP (1) EP0989993B1 (is)
JP (1) JP3414759B2 (is)
KR (1) KR100339936B1 (is)
CN (2) CN1524857A (is)
AP (1) AP1043A (is)
AR (1) AR012255A1 (is)
AT (1) ATE388163T1 (is)
AU (1) AU744775B2 (is)
BG (1) BG104024A (is)
BR (1) BR9810623B1 (is)
CA (1) CA2294422C (is)
CO (1) CO4810383A1 (is)
DE (1) DE69839211T2 (is)
DK (1) DK0989993T3 (is)
DZ (1) DZ2538A1 (is)
EA (1) EA002643B1 (is)
ES (1) ES2301196T3 (is)
GT (1) GT199800085A (is)
HR (1) HRP980362A2 (is)
HU (1) HUP0002664A3 (is)
ID (1) ID23188A (is)
IL (1) IL132810A0 (is)
IS (1) IS5276A (is)
MA (1) MA26516A1 (is)
NO (1) NO996469L (is)
NZ (1) NZ500658A (is)
OA (1) OA11241A (is)
PA (1) PA8453401A1 (is)
PE (1) PE97599A1 (is)
PL (1) PL337654A1 (is)
PT (1) PT989993E (is)
SK (1) SK177299A3 (is)
TN (1) TNSN98111A1 (is)
TR (1) TR199903261T2 (is)
TW (1) TWI221153B (is)
UA (1) UA53716C2 (is)
UY (1) UY25059A1 (is)
WO (1) WO1998058948A1 (is)
ZA (1) ZA985541B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
EP1313473A2 (en) * 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
PT1326851E (pt) * 2000-10-13 2004-11-30 Lilly Co Eli Dipeptidos substituidos como secretagogues da hormona do crescimento
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005097788A2 (en) * 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
KR100641571B1 (ko) * 2005-01-05 2006-10-31 주식회사 팬택앤큐리텔 이동통신 단말기에서의 클럭 발생 장치
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
WO2012171987A1 (en) * 2011-06-16 2012-12-20 Lonza Ltd A process for extraction of peptides and its application in liquid phase peptide synthesis
US9949992B2 (en) * 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US9833411B2 (en) 2015-01-12 2017-12-05 Enteris Biopharma, Inc. Solid oral dosage forms
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPH08503213A (ja) 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
PL176993B1 (pl) 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
EP0739204A4 (en) * 1993-11-09 2000-03-15 Merck & Co Inc PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
DK0989993T3 (da) 2008-06-02
UA53716C2 (uk) 2003-02-17
PT989993E (pt) 2008-04-15
MA26516A1 (fr) 2004-12-20
PE97599A1 (es) 1999-10-12
AP9801266A0 (en) 1998-06-30
AU7445598A (en) 1999-01-04
BR9810623B1 (pt) 2010-06-15
CN1314912A (zh) 2001-09-26
AU744775B2 (en) 2002-03-07
EP0989993B1 (en) 2008-03-05
SK177299A3 (en) 2001-09-11
IL132810A0 (en) 2001-03-19
US6596867B2 (en) 2003-07-22
PL337654A1 (en) 2000-08-28
PA8453401A1 (es) 2000-05-24
OA11241A (en) 2003-05-26
EP0989993A1 (en) 2000-04-05
HUP0002664A3 (en) 2001-12-28
AR012255A1 (es) 2000-09-27
BG104024A (bg) 2000-07-31
UY25059A1 (es) 2000-12-29
TR199903261T2 (xx) 2000-08-21
DE69839211T2 (de) 2009-03-19
JP2000514840A (ja) 2000-11-07
US6248717B1 (en) 2001-06-19
HRP980362A2 (en) 1999-02-28
ZA985541B (en) 2000-01-10
GT199800085A (es) 1999-12-10
EA199901076A1 (ru) 2000-08-28
CA2294422C (en) 2003-07-22
CA2294422A1 (en) 1998-12-30
CO4810383A1 (es) 1999-06-30
TNSN98111A1 (fr) 2005-03-15
NO996469L (no) 2000-02-23
JP3414759B2 (ja) 2003-06-09
KR20010014153A (ko) 2001-02-26
CN1524857A (zh) 2004-09-01
HUP0002664A2 (hu) 2000-12-28
TWI221153B (en) 2004-09-21
AP1043A (en) 2002-02-04
ID23188A (id) 2000-03-23
ATE388163T1 (de) 2008-03-15
KR100339936B1 (ko) 2002-06-10
NZ500658A (en) 2001-08-31
US20010016570A1 (en) 2001-08-23
EA002643B1 (ru) 2002-08-29
BR9810623A (pt) 2000-07-25
ES2301196T3 (es) 2008-06-16
DZ2538A1 (fr) 2003-02-08
DE69839211D1 (de) 2008-04-17
NO996469D0 (no) 1999-12-23
WO1998058948A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
IS5276A (is) Tartrat salt af setnu dípeptíði sem vaxtarhormónsseytir
DE69837264D1 (de) Dipeptidderivate zur förderung der sekretion von wachstumshormon
IS4758A (is) Efnasambönd sem örva seyti vaxtarhormóna
AU7641801A (en) Alpha crystalline form of perindopril tert-butylamine salt
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
NO20001242L (no) April - et nytt protein med veksteffekter
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
PL338883A1 (en) Growth hormone secretion stimulating compounds
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
ATE362472T1 (de) Wachstumhormonsekretionsförderer
IS5989A (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
EP1137805A4 (en) METHODS FOR FACILITATING VASCULAR GROWTH
HUP0103072A3 (en) Use of growth hormone secretagogues
AU4329499A (en) Reduced dipeptide analogues as calcium channel antagonists
ATE339438T1 (de) Substanziell kristalline form von melagatran
DK1031575T3 (da) Fremgangsmåde til fremstilling af væksthormonsekretionsfremkaldende midler
IS4721A (is) Margbreytileg form af vaxtarhormóna seytisörvara (secretagogue)
EP1373299A4 (en) Connective tissue GROWTH FACTOR-2
FI972968A (fi) Menetelmiä kasvuhormonivaikutusten estämiseksi
IL160678A0 (en) Tartrate salt of a substituted dipeptide as growth hormone secretagogue
SI1326851T1 (en) Substituted dipeptides as growth hormone secretagogues
AU2003236478A1 (en) Therapeutic Uses of Keratinocyte Growth Factor-2
SI0941110T1 (en) Uses of keratinocyte growth factor-2
ID25905A (id) Komposisi topikal yang mengandung faktor pertumbuhan epidermal manusia
SI0991641T1 (en) Crystalline form of omeprazole sodium salt